University of Leeds spinout adsilico has secured £10 million in a Series A funding round to scale its generative artificial intelligence platform designed for testing medical devices on virtual patient populations. The financing was spearheaded by PXN Ventures, with continued support from earlier backers Northern Gritstone and Parkwalk. While initial reports from Tech.eu list three founders, the company's official documentation expands this roster to include Professor Alejandro Frangi alongside Sheena Macpherson, Dr. Nishant Ravikumar, and Dr. Zeike Taylor. The startup leverages computational methods to evaluate device performance before physical trials begin.
Generating Synthetic Populations with Virtual Chimera
Adsilico operates around a core technology called Virtual Chimera, which employs generative AI to construct synthetic hearts and blood vessels derived from anonymized clinical scans. These digital models incorporate patient variations across age, sex, ethnicity, body size, and underlying medical conditions. By coupling these anatomies with physics-based simulations, manufacturers can observe how implants behave within diverse anatomical environments. According to company materials, virtual populations are validated against real patient data under clinical oversight, ensuring that the synthetic cohorts accurately reflect clinical realities while exposing no real individuals to testing risks.
Expanding Beyond Cardiac Care into Neurovascular Devices
Traditional clinical trials for medical devices like stents and heart valves often rely on a few hundred participants, creating significant demographic representation gaps and incurring high costs. Adsilico's platform helps manufacturers navigate these hurdles by offering early insights into device sizing, patient risk stratification, and trial optimization. The newly acquired capital will directly fund workforce expansion and drive the company's entry into neurovascular applications, including flow diverters used in treating brain aneurysms. The startup has already completed projects with heart valve and neurovascular device developers, with cardiac research scheduled for presentation at the TCT conference.
Regulatory Alignment and the Shift Toward Digital Evidence
The investment in adsilico underscores a broader shift in the medical technology sector toward integrating computational modeling and simulation as a credible source of evidence alongside traditional clinical trials. Device manufacturers face immense pressure to accelerate development timelines while ensuring safety across varied patient demographics that are rarely fully captured in standard trials. By aligning model credibility assessments with the risk-informed principles of ASME V&V 40—upon which recent FDA guidance is built—platforms like Virtual Chimera aim to facilitate more robust regulatory conversations and reduce reliance on animal testing. However, computational insights are designed to answer specific investigative questions rather than serve as blanket regulatory approvals. For device makers, adopting these virtual workflows offers a way to preemptively identify failure points, minimize costly design errors, and design more inclusive studies that benefit patient populations historically overlooked in medical research.
Validation, Clinical Oversight, and Growth Plans
Backed by over fifteen years of underlying academic research, adsilico blends computational science with clinical expertise. The firm works alongside clinical advisors, such as cardiothoracic surgeon Dr. Stuart Grant, to ensure simulation outcomes align with clinical practice. As the company scales its operations following the Series A investment, it intends to deepen its therapeutic reach, refine its virtual heart and vessel models, and grow its team of specialists to support device manufacturers approaching pivotal regulatory and feasibility decisions.
Editorial graphic and headline text by Signal Titans.
Source: Leeds AI spinout adsilico raises £10M to test medical devices on virtual patients · adsilico | In silico insights for implantable devices
SIGNAL TITANS
Leave a Reply